Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance

Morton Coleman, MD FACP, David Jacob Andorsky, MD, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Frederick Lansigan, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD PhD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-134363

Published: 2020

Journal Articles

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, MD PhD, Alison J. Moskowitz, MD, Neha Mehta-Shah, MD, Lubomir Sokol, MD PhD, Zhengming Chen, PhD MPH, MS, Riyaad Rahim, Wei Song, Koen Van Besien, MD PhD, Steven M. Horwitz, MD, Sarah C. Rutherford, MD, Morton Coleman, MD FACP, Ari Melnick, MD, Giorgio Inghirami, MD, Leandro Cerchietti, MD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136023

Published: 2020

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134611

Published: 2020

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Frederick Lansigan, MD, David Jacob Andorsky, MD, Morton Coleman, MD FACP, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD PhD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134193

Published: 2020

Journal Articles

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma

Cara A. Rosenbaum, MD, Danny Luan, BS, MPH, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Koen Van Besien, MD PhD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 2026.

https://doi.org/10.1182/blood-2019-127710

Published: 2019

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Eloisi Caldas Lopes, PhD, Tai Wang, PhD, David S Jayabalan, MSc, Tony Taldone, PhD, Jorge Monge, MD, Jorge Contreras, MD, Yip Winnie, Vicenta Trujillo, PhD, Panchal Palak, Nicholas Lombardi, Sharma Sahil, PhD, Digwal Chander, PhD, Morton Coleman, MD, Gabriela Chiosis, PhD, Ruben Niesvizky, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 4399.

https://doi.org/10.1182/blood-2019-125267

Published: 2019

Journal Articles

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Danny Luan, BS, MPH, Koen Van Besien, MD PhD, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2019) 134 (Supplement_1): 4579.

https://doi.org/10.1182/blood-2019-127723

Published: 2019

Journal Articles

Autologous Stem Cell Transplantation Outcomes in Patients with Myeloma and Renal Dysfunction

Jorge Monge, MD, David S Jayabalan, MSc, Ruben Niesvizky, MD, Morton Coleman, MD, Kari Flicker, BS, Robin S. Solomon, Adriana C. Rossi, MDMSc, Jin Guo, MD

Blood (2019) 134 (Supplement_1): 5573.

https://doi.org/10.1182/blood-2019-131919

Published: 2019

Journal Articles

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Blood (2019) 134 (Supplement_1): 5644.

https://doi.org/10.1182/blood-2019-130914

Published: 2019

Journal Articles

Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution

Jorge Monge, MD, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Jin Guo, MD, Jorge Contreras, MD, Kathleen Pogonowski, RN, Natalie Agudo, RN, Danielle Guarneri, BS, CCRP, Brielle Liotta, BS, Eloisi Caldas Lopes, PhD, Roger Pearse, MD PhD, Morton Coleman, MD, Ruben Niesvizky, MD, Adriana C. Rossi, MDMSc

Blood (2019) 134 (Supplement_1): 5563.

https://doi.org/10.1182/blood-2019-127697

Published: 2019

Journal Articles

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Jorge Monge, MD, Jorge Contreras, MD, Sarah Elsoukkary, MD, Jin Guo, MD, Art Perry, PA, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Morton Coleman, MD, Adriana C. Rossi, MDMSc, Rebecca Harris, MD, Markus Plate, MD, Joerg-Patrick Stuebgen, MB, ChB, MD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 4876.

https://doi.org/10.1182/blood-2019-122134

Published: 2019

Journal Articles

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

Tycel J. Phillips, MD, Stephen D. Smith, MD, Wojciech Jurczak, Tadeusz Robak, MD PhD, Don Stevens, MD, Charles M. Farber, MD PhD, John M. Pagel, MD PhD, Kami J. Maddocks, MD, Ian W. Flinn, MD PhD, Wieslaw W. Jedrzejczak, MD PhD, Andre Goy, MD, Pier Luigi Zinzani, MD, Jan Zaucha, MD PhD, Morton Coleman, MD, Tianling Chen, MD, Sun Ku Lee, PhD, Wei Liang, PhD, Anna Seto, PharmD, Michael Wang, MD

Blood (2018) 132 (Supplement 1): 4144.

https://doi.org/10.1182/blood-2018-99-110617

Published: 2018

Journal Articles

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Aneel Paulus, MD, Alak Manna, PhD, Sharoon Akhtar, MPhil, Neeraj Kumar Singh, B.Tech, Ansu Kumar, MS, Kabya Basu, MS, Akshita Trivedi, B.Tech, Debapriya Majumdar, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Vivek Roy, MD, Peter Martin, FRCPC, MD MS, Morton Coleman, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 1260.

https://doi.org/10.1182/blood.V130.Suppl_1.1260.1260

Published: 2017

Journal Articles

A Phase II Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed By Autologous Stem Cell Transplant for Patients with Multiple Myeloma

Alexandra Gomez-Arteaga, MD, Tomer M Mark, MDMSc, Danielle Guarneri, Paul J Christos, Dr.P.H., M.S., Usama Gergis, MD, June Greenberg, RN, Jingmei Hsu, MD PhD, Sebastian A. Mayer, MD, Ruben Niesvizky, MD, Roger Pearse, MD PhD, Adrienne A. Phillips, MD MPH, Adriana C. Rossi, MDMSc, Morton Coleman, MD, Koen Van Besien, MD PhD, Tsiporah B. Shore, MD

Blood (2017) 130 (Supplement 1): 4546.

https://doi.org/10.1182/blood.V130.Suppl_1.4546.4546

Published: 2017

Journal Articles

Ibrutinib Therapy in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Analysis By Prior Rituximab Treatment and Baseline Mutations

Blood (2017) 130 (Supplement 1): 3026.

https://doi.org/10.1182/blood.V130.Suppl_1.3026.3026

Published: 2017

Journal Articles

Targeting CD38 with Daratumumab Suppresses B-Cell Receptor Signaling and Enhances the Activity of Ibrutinib in Waldenstrom Macroglobulinemia Cells

Aneel Paulus, MD, Alak Manna, PhD, Sharoon Akhtar, MPhil, Taimur Sher, MD, Vivek Roy, MD, Morton Coleman, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD, Fabio Malavasi, MD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 1529.

https://doi.org/10.1182/blood.V130.Suppl_1.1529.1529

Published: 2017

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Jia Ruan, MD PhD, Peter Martin, FRCPC, MD MS, Paul J Christos, Dr.P.H., M.S., Leandro Cerchietti, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Wayne Tam, MD PhD, Amelyn Rodriguez, BSN, RN, OCN, David Hyman, Maria Nieves Calvo Vidal, PhD, Lidia Roman Gonzalez, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2017) 130 (Supplement 1): 154.

https://doi.org/10.1182/blood.V130.Suppl_1.154.154

Published: 2017

Journal Articles

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Peter A. Forsberg, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, John N. Allan, MD, Ruben Niesvizky, MD, Tomer Mark, MD MSc

Blood (2016) 128 (22): 4518.

https://doi.org/10.1182/blood.V128.22.4518.4518

Published: 2016

Journal Articles

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Ariela Noy, MD PhD, Sven de Vos, MD PhD, Catherine Thieblemont, MD PhD, Peter Martin, MD, Christopher Flowers, MDMS, Franck Morschhauser, Graham P. Collins, MD PhD, Shuo Ma, Morton Coleman, MD, Shachar Peles, MD, Stephen Smith, MD, Alina Smith, Brian Munneke, PhD, Isaiah Dimery, MD, Darrin Beaupre, MD PhD, Robert W Chen, MD

Blood (2016) 128 (22): 1213.

https://doi.org/10.1182/blood.V128.22.1213.1213

Published: 2016

NARROW

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Autologous Stem Cell Transplantation Outcomes in Patients with Myeloma and Renal Dysfunction

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

A Phase II Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed By Autologous Stem Cell Transplant for Patients with Multiple Myeloma

Ibrutinib Therapy in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Analysis By Prior Rituximab Treatment and Baseline Mutations

Targeting CD38 with Daratumumab Suppresses B-Cell Receptor Signaling and Enhances the Activity of Ibrutinib in Waldenstrom Macroglobulinemia Cells

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only